EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Erythromycin Emerges as a MERS‐CoV Papain‐Like Protease Inhibitor: Unveiling a Dual Mechanism of Thermal Stabilization and Conformational Restriction

Ahmed L. Alaofi, Mudassar Shahid, Ehab Taha, Mohd Abul Kalam

Journal of Chemistry · 2026-01 · 2026 (1)

DOI: 10.1155/joch/8866522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chemistry, online erschienen am 07.10.2026. Verfasst von Ahmed L. Alaofi und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite its public health risk and case fatality rate exceeding 35%, there are currently no approved treatments for Middle East Respiratory Syndrome coronavirus (MERS‐CoV). This study investigates the potential of selected antibiotics—erythromycin, linezolid, delafloxacin, and gemifloxacin—as inhibitors of MERS‐CoV papain‐like protease (PLpro), a crucial enzyme for viral replication and immune evasion.

Methods

We assessed the binding and inhibitory effects of four antibiotics on recombinant MERS‐CoV PLpro using thermal shift assays (TSAs), FRET‐based enzyme inhibition assays with a fluorogenic peptide substrate, molecular dynamics (MD) simulations, and MM‐GBSA binding free energy calculations. Dose–response curves were generated to determine IC 50 values, and computational analyses evaluated binding mechanisms and protein conformational changes.

Results

Erythromycin demonstrated notable dose‐dependent inhibition with an IC 50 of 7.089 μM, while other antibiotics showed no significant activity. TSA analysis revealed an exceptional thermal stabilization effect (ΔTm = +19.75°C), confirming strong PLpro binding. MD simulations showed erythromycin stabilizes PLpro while restricting conformational flexibility by 21–43% depending on the metric used. MM‐GBSA calculations yielded a favorable binding free energy (Δ G = −24.19 ± 2.93 kcal/mol), strongly corroborating experimental inhibition data. The binding is driven primarily by van der Waals interactions (−37.46 kcal/mol) through a hydrophobically driven, electrostatically stabilized interface that reduces local flexibility in functional domains.

Conclusions

Erythromycin emerges as a promising candidate for repurposing as a MERS‐CoV antiviral, operating through a unique dual mechanism of enzymatic inhibition and conformational restriction. The strong experimental‐computational agreement validates structure‐based drug repurposing approaches and positions erythromycin for immediate clinical evaluation given its established safety profile and clinically achievable plasma concentrations.

Förderung

  • King Saud University

Zitieren

APA

Alaofi, A. L., Shahid, M., Taha, E., & Kalam, M. A. (2026). Erythromycin Emerges as a MERS‐CoV Papain‐Like Protease Inhibitor: Unveiling a Dual Mechanism of Thermal Stabilization and Conformational Restriction. Journal of Chemistry, 2026(1). https://doi.org/10.1155/joch/8866522

Vancouver

Alaofi AL, Shahid M, Taha E, Kalam MA. Erythromycin Emerges as a MERS‐CoV Papain‐Like Protease Inhibitor: Unveiling a Dual Mechanism of Thermal Stabilization and Conformational Restriction. Journal of Chemistry. 2026;2026(1). doi:10.1155/joch/8866522

BibTeX
@article{Alaofi2026,
  author = {Alaofi, Ahmed L. and Shahid, Mudassar and Taha, Ehab and Kalam, Mohd Abul},
  title = {Erythromycin Emerges as a MERS‐CoV Papain‐Like Protease Inhibitor: Unveiling a Dual Mechanism of Thermal Stabilization and Conformational Restriction},
  journal = {Journal of Chemistry},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/joch/8866522}
}
Kostenlos starten →